More recently, pembrolizumab has been approved by the FDA as a first-line treatment itself in R/M HNSCC: in monotherapy (only in patients expressing high rates of PD-L1) or in combination with standard chemotherapeutic agents [3]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.